Targeting survivin and p53 in pediatric acute lymphoblastic leukemia

Despite advances in treatment and outcomes for patients with pediatric acute lymphoblastic leukemia (ALL), there continue to be subsets of patients who are refractory to standard chemotherapy and hematopoietic stem cell transplant. Therefore, novel gene targets for therapy are needed to further adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyner, J W, Jemal, A M, Thayer, M, Druker, B J, Chang, B H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364442/
https://www.ncbi.nlm.nih.gov/pubmed/21960246
http://dx.doi.org/10.1038/leu.2011.249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364442/
https://www.ncbi.nlm.nih.gov/pubmed/21960246
http://dx.doi.org/10.1038/leu.2011.249

Ejemplares similares